Results 81 to 90 of about 8,509,826 (346)

Objective response rate of placebo in randomized controlled trials of anticancer medicinesResearch in context

EClinicalMedicine, 2023
Summary: Background: Spontaneous regression of advanced solid tumors is infrequent but may occur. Quantifying response rates from placebo in cancer drug trials may provide important information for physicians, patients, and regulators.
Arushi Sachdev, Isobel Sharpe, Meghan Bowman, Christopher M. Booth, Bishal Gyawali   +4 more
doaj  

Increasing effort without noticing: A randomized controlled pilot study about the ergogenic placebo effect in endurance athletes and the role of supplement salience. [PDF]

PLoS ONE, 2018
PurposePrevious research shows that endurance performance can be enhanced by placebo ergogenic aids. This study investigates the ergogenic placebo response, which we define as an increase in objective and physiological effort without an increase in ...
Ellen K Broelz, Sebastian Wolf, Patrick Schneeweiss, Andreas M Niess, Paul Enck, Katja Weimer   +5 more
doaj   +1 more source

The Meaning Response, "Placebo," and Methods [PDF]

Perspectives in Biology and Medicine, 2018
In 2002, Dan Moerman outlined three candidate explanations for the "placebo response": the "conditioned stimulus-response," Irving Kirsch's "response-expectancy" explanation, and the "meaning response." The meaning response, Moerman argued, was the only one of the three candidate explanations that could cover all the data, gained from decades of RCTs ...
Phil Hutchinson, Daniel E. Moerman
openaire   +3 more sources

Integration of white matter network is associated with interindividual differences in psychologically mediated placebo response in migraine patients

Human Brain Mapping, 2017
Individual differences of brain changes of neural communication and integration in the modular architecture of the human brain network exist for the repeated migraine attack and physical or psychological stressors.
Jixin Liu, S. Ma, J. Mu, Tao Chen, Qing Xu, Wang-huan Dun, Jie Tian, Ming Zhang   +7 more
semanticscholar   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis

BMC Musculoskeletal Disorders, 2018
Background Pain is the principal clinical symptom of osteoarthritis (OA), and development of safe and effective analgesics for OA pain is needed. Drug development of new analgesics for OA pain is impaired by substantial change in pain in patients ...
Asger Reinstrup Bihlet, Inger Byrjalsen, Anne-Christine Bay-Jensen, Jeppe Ragnar Andersen, Claus Christiansen, Bente Juel Riis, Ivo Valter, Morten A. Karsdal, Marc C. Hochberg   +8 more
doaj   +1 more source

Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome

Frontiers in Pain Research, 2022
Background and Aims: Irritable bowel syndrome (IBS), a functional pain disorder of gut-brain interactions, is characterized by a high placebo response in randomized clinical trials (RCTs).
Rui-Sheng Wang, Rui-Sheng Wang, Anthony J. Lembo, Anthony J. Lembo, Ted J. Kaptchuk, Ted J. Kaptchuk, Vivian Cheng, Judy Nee, Judy Nee, Johanna Iturrino, Johanna Iturrino, Meenakshi Rao, Meenakshi Rao, Joseph Loscalzo, Joseph Loscalzo, Jocelyn A. Silvester, Jocelyn A. Silvester, Jocelyn A. Silvester, Jocelyn A. Silvester, Kathryn T. Hall, Kathryn T. Hall, Kathryn T. Hall   +21 more
doaj   +1 more source

Relationship Between Gout Flare States and Patient‐Reported Outcomes After Allopurinol Initiation

Arthritis Care &Research, EarlyView.
Objective Gout flares are the most important clinical feature of the disease. A hypothetical maximum flare occurrence in the preceding six months has been suggested to be no flares for a patient‐acceptable symptom state (PASS) and only one flare for low disease activity (LDA).
Lisa K. Stamp, Chris Frampton, Sarah Stewart, Keith J. Petrie, N. Lawrence Edwards, Angelo Gaffo, Nicola Dalbeth   +6 more
wiley   +1 more source

A Single Index Model for Longitudinal Outcomes to Optimize Individual Treatment Decision Rules [PDF]

arXiv, 2022
A pressing challenge in medical research is to identify optimal treatments for individual patients. This is particularly challenging in mental health settings where mean responses are often similar across multiple treatments. For example, the mean longitudinal trajectories for patients treated with an active drug and placebo may be very similar but ...
arxiv  

Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation.

Journal of child and adolescent psychopharmacology, 2016
OBJECTIVES The characterization and prediction of placebo response in clinical trials of youth with anxiety disorders have received little attention, despite the critical effects of placebo response rate on the success or failure of clinical trials. With
Eric T. Dobson, J. Strawn
semanticscholar   +1 more source